Merck agrees to multi-year research collaboration with Quotient Therapeutics in a deal worth up to $2.2 billion to use somatic genomics and AI-driven analytics to identify new drug targets for inflammatory bowel disease.
Merck enters a multi-year research collaboration with Quotient Therapeutics to identify novel drug targets for inflammatory bowel disease using the company’s somatic genomics platform.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The partnership reflects growing interest in leveraging naturally occurring genetic variation within patient tissues to uncover new therapeutic pathways.
Somatic mutations accumulate over a lifetime, creating extensive genetic diversity across cells within an individual. Quotient’s approach focuses on analyzing these mutations directly in diseased tissue to identify variants that may drive or protect against disease, with the aim of informing more precise therapeutic strategies in conditions where treatment options remain limited.2
“The combination of Merck’s deep drug development and global commercial expertise with our unbiased, disease- and modality-agnostic somatic genomics platform could redefine how IBD is understood and treated,” said Rahul Kakkar, MD, president and chief executive officer of Quotient. “We are proud to work alongside the world-class team at Merck, broadening the reach of our somatic genomics platform and bringing potentially breakthrough therapies to the patients in need.”
Under the agreement, Quotient will receive a $20 million upfront payment and is eligible for development, regulatory, and commercial milestones totaling up to $2.2 billion.1
Quotient was launched by Flagship Pioneering back in 2023 with an initial $50 million commitment to advance its somatic genomics platform and build a pipeline across multiple therapeutic areas.2
The company has since developed a scalable discovery engine supported by more than three years of somatic data spanning 15 diseases, integrating artificial intelligence and computational biology across its research workflows.3
“Quotient’s platform has the potential to provide us with unique biological insights into genomic changes that are naturally occurring within patients with IBD. Millions of people globally are living with this disease, and no disease-modifying treatments are currently available,” said Dr. Marc Levesque, vice president, discovery, Merck Research Laboratories. “Immunology is a key area of focus for Merck, and we look forward to collaborating on this novel approach to target discovery to help us develop more effective therapeutic options for patients.”
The platform uses high-sensitivity sequencing to identify mutations that either cause or protect against disease, generating genetically validated insights for drug development.
Because somatic mutations are widespread, often numbering in the hundreds or thousands per cell, Quotient can identify meaningful disease signals from relatively small patient cohorts, typically between 10 and 30 individuals, compared with the much larger populations required for traditional genetic studies.3
By detecting recurrent mutations directly within the cells driving disease, the approach is designed to improve confidence that identified targets are causally linked to disease biology.
The data can also inform drug design, including which biological pathways to target, how to intervene based on mutation type and function, and where within a gene or protein to focus therapeutic activity.3
From sample collection through target identification and validation, the platform incorporates AI-enabled analytics and automated workflows to accelerate discovery.3
This high-throughput, data-driven model reflects a broader industry shift toward integrating advanced computational tools with human-derived biological data.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
